TILRAY Aktie

 

In the latest trading session, Tilray Brands, Inc. (TLRY) closed at $1.25, marking a -9.42% move from the previous day....

From Hype to Hiccups in the Cannabis Craze Once hailed as the “next big thing,” cannabis stocks in 2018-2019 were the artificial intelligence stock darlings of their day, riding a wave of euphoria over impending federal legalization in the U.S.  Companies like Canopy Growth (NASDAQ:CGC), Tilray Brands (NASDAQ:TLRY), and Aurora Cannabis (NASDAQ:ACB) saw valuations soar […] The post Pot Stocks Plunge After Rally: Is Betting on Rescheduling Worth the Risk? appeared first on 24/7 Wall St.....

The company's trajectory in recent years suggests one clear answer....

Tilray bekräftigt sein anhaltendes Engagement für das deutsche Gesundheitswesen und den Ausbau des Zugangs für Patienten und Apotheken auf Europas größtem Markt für medizinisches Cannabis Tilray bekräftigt sein anhaltendes Engagement für das deutsche Gesundheitswesen und den Ausbau des Zugangs für Patienten und Apotheken auf Europas größtem Markt für medizinisches Cannabis...

Tilray shares rose ~5% after launching three EU-GMP medical cannabis strains in Germany and confirming renewed Nasdaq bid-price compliance. read more...

Tilray Affirms Continued Commitment to German Healthcare and Expanding Patient and Pharmacy Access in Europe's Largest Medical Cannabis Market Tilray Affirms Continued Commitment to German Healthcare and Expanding Patient and Pharmacy Access in Europe's Largest Medical Cannabis Market...

The latest trading day saw Tilray Brands, Inc. (TLRY) settling at $1.37, representing a -5.52% change from its previous close....

NEW YORK and LEAMINGTON, Ontario, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today announced that it received written notice from the Nasdaq Stock Market, LLC (“Nasdaq”) confirming that Tilray is again in compliance with Nasdaq's minimum bid price requirement set forth in 5450(a)(1) of the Nasdaq Listing Rules. To achieve this, the Company's shares were required to close at $1.00 or higher for at least 10 consecutive trading days. According to Nasdaq's notice, Tilray maintained a closing bid price of at least $1.00 for 10 consecutive trading days from August 13, 2025 to August 26, 2025, thereby meeting the minimum bid price requirement. As a result, Nasdaq has closed the matter....

Die Tilray-Aktie profitiert derzeit von US-Präsident Trumps Plänen zur Herabstufung von Cannabis in der Drogenklassifizierung....

Die Tilray-Aktie profitiert derzeit von US-Präsident Trumps Plänen zur Herabstufung von Cannabis in der Drogenklassifizierung....

With rescheduling on the table, here are two option trades to play the potential spike in TLRY stock....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

US-Präsident Donald Trump will Marihuana von der strengsten Einstufung als Schedule I auf Schedule III herabstufen. Jefferies-Analyst Kaumil Gajrawala hat daraufhin das Kursziel für die Aktie des kanadischen Brancheriesen Tilray auf 2,00 US-Dollar angehoben. "Wir werden bald mit der Neubewertung von Marihuana voranschreiten", erklärte Trump zuletzt und räumte ein: "Es ist ein sehr komplexes Thema." Für Analyst Gajrawala ein wichtiges Signal für die Branche. "Dies wäre zwar keine vollständige Legalisierung, aber dennoch eine bedeutende Änderung der Cannabispolitik auf Bundesebene, die den ins Stocken geratenen Überprüfungsprozess der DEA möglicherweise beschleunigen würde."

Pharmaceuticals and cannabis lifestyle company, Tilray Brands Inc. (NASDAQ: TLRY), rallied 20.87% on Monday and is now showing no signs of slowing down, with another 4.32% gain after hours, as broad-based tailwinds begin to align in the company's favor. read more...

U.S. stocks closed lower on Monday, with the Dow Jones Industrial Average slipping almost 0.8% to 45,282.47. read more...

Tilray stock extends gains as Jefferies raises its price target on the cannabis firm to $2. But caution is warranted as TLRY shares are already up some 300% versus their year-to-date low....

New York (www.aktiencheck.de) - Tilray-Aktienanalyse von Jefferies & Co: Jefferies & Co habe das Kursziel für die Aktie von Tilray Brands Inc. (ISIN: US88688T1007, WKN: A2JQSC, Ticker-Symbol: 2HQ, NASDAQ-Symbol: TLRY) von 1,50 auf 2 USD angehoben und das Rating "buy" bestätigt. Analyst Kaumil Gajrawala sehe darin eine deutliche Verbesserung der Rahmenbedingungen, nachdem Ex-Präsident Trump jüngst signalisiert habe, Cannabis von Schedule I auf Schedule III herabstufen zu wollen. [mehr]...

Tilray stock has surged on the prospect of U.S. cannabis reclassification and new medical partnerships, but analysts urge caution as sustainable profits and steady execution remain key to long-term upside.......

With global ambitions expanding and potential cannabis reclassification, should investors brace for upside? Or prepare for another volatile season?...

Tilray and the rest of the cannabis industry have not delivered on the hype....